RBDCOV: EATG represents community in a new project aiming to study COVID-19 vaccine

Back to the "News" list

EATG is participating in RBDCOV, a project aiming to study a COVID-19 vaccine in children, adolescents and immunocompromised patients. Drawing from its experience in patients’ advocacy and representation, EATG will contribute to the studies through community insights and outreach.


Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein. “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) was launched on 1st December. The trials will last 2.5 years.


Find more information about RBDCOV in this press release.

The RBDCOV project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101046118

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.